Sanobiotec is a family of intertwined companies, each of them being unique in purpose and approach. Nonetheless, collectively we are a Lithuania based startup that began back in 2018, when a group of specialists gathered for a purpose of helping our loved ones, friends and everyone within the reach. We know firsthand how detrimental cancer, insomnia, arthritis, epilepsy, obesity and other illnesses can be, what is more, increasingly more research globally shows the potential for tackling these issues with cannabinoids. That is why we began as a research facility, earned our trust from local institutions and began searching for cannabinoids and their derivatives for cancer treatment.  

Along the way we understood the potential and the need for minor cannabinoids as the market was being filled with poor quality and unsatisfying purity products. This brought us to a new chapter in our story – we began offering minor cannabinoids worldwide, built a factory and developed large scale production capabilities in a single year despite all global turbulences that have come in 2020. Our passionate, young, creative and unbreakable team has overcome each and every stone we have stumbled upon in our path. Our work and achievements truly define who we are – a diverse team of persistent thinkers and achievers. 

We are a global bulk ingredient manufacturer. Sanobiotec manufactures isolates as well as various oils and liquids. Our portfolio includes the sought-after minor cannabinoids: CBN, CBC, CBDV, CBGA and CBDA isolates, and the more mainstream natural CBD and CBG isolates. Decades of accumulated experience and knowledge allows us to provide you with copious amounts of both natural and (semi) synthetic compounds at the highest purity. Purity, we believe, is the key factor in wellness, cosmetics and food related markets, where customer satisfaction reviews decide the fate of any brand.

Our R&D facility push boundaries in the field of cannabinoids through partnership with national and educational institutions. Our work with the National Cancer Institute of Lithuania includes extraction and synthesis of minor cannabinoids and derivatives in an attempt to tackle specific cancers. Another partnership connects us with Life Science Centre of Vilnius University – our colleagues in development of recombinant yeast strains to produce cannabinoids biosynthetically and to perform in vivo experiments.